Natalia Pozdniakova

Dr. Natalia Pozdniakova

Russian Cancer Research Center NN Blokhin, Moscow, Moskva, Russia
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2007 in Biochemistry (Moscow)
Verified
Journal Article
Closed access
PDF file
ADA. V. Digtyar
A. V. Digtyar
Natalia PozdniakovaNatalia Pozdniakova
Natalia Pozdniakova
NFNataliya Feldman
Nataliya Feldman
SLS. V. Lutsenko
S. V. Lutsenko
SSS. E. Severin
S. E. Severin
Endogenous inhibitors of angiogenesis are proved to be a major factor preventing the emergence of clinically manifested stages of human cancer. The protein endostatin, a 20-kD proteolytic fragment of...

7 October 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Natalia PozdniakovaNatalia Pozdniakova
Natalia Pozdniakova
EGEvgenii Generalov
Evgenii Generalov
ASAlexei B Shevelev
Alexei B Shevelev
Olga TarasovaOlga Tarasova
Olga Tarasova
RNA-based therapeutics offer transformative potential for treating devastating diseases. However, current RNA delivery technologies face significant hurdles, including inefficient tissue targeting, insufficient selectivity, and severe side effects, leading to the termination of many clinical trials. This review critically assesses the landscape of RNA-derived medicines, examining world-renowned mRNA vaccines (Spikevax, BNT162b2/Comirnaty) and RNA-based therapeutics like Miravirsen (anti-miR-122). It details the composition and clinical trial results of numerous modified short RNA drugs (e.g., siRNAs, miRNA mimetics/inhibitors) targeting various conditions. Prospects for RNA-based medicines are analysed for diseases with substantial societal impact, such as cancer, autoimmune disorders, and infectious diseases, with a focus on evolving delivery methods, including lipid nanoparticles, viral vectors, and exosomes. RNA-mediated macrophage reprogramming emerges as a promising strategy, potentially enhancing both delivery and clinical efficacy. This review highlights that while approved RNA therapies primarily target rare diseases due to delivery limitations, novel approaches in RNA modification, targeted delivery systems, and enhanced understanding of molecular mechanisms are crucial for expanding their application to prevalent diseases and unlocking their full therapeutic potential.

Verified
Journal Article
Open access
PDF file
ASAlexei B Shevelev
Alexei B Shevelev
Natalia PozdniakovaNatalia Pozdniakova
Natalia Pozdniakova
EGEvgenii Generalov
Evgenii Generalov
Olga TarasovaOlga Tarasova
Olga Tarasova
RNA-based drugs hold significant potential, offering promising new treatments for a wide range of diseases, especially those with a genetic basis. By leveraging RNA interference (RNAi) and other RNA-mediated mechanisms, these therapies can precisely modulate gene expression and address the root causes of genetic defects. RNA-based drugs hold significant potential for treating a range of diseases. However, the transition of these therapies from laboratory research to clinical applications has encountered hurdles. This review explores the composition and outcomes of clinical trials for various modified short RNA drugs. We detail their mechanisms of action, delivery systems—with a focus on lipid nanoparticles and N-acetylgalactosamine (GalNAc) conjugates—and clinical efficacy in treating conditions such as transthyretin (TTR) amyloidosis. Our analysis reveals that while several RNAi-based drugs have achieved clinical approval, a critical unmet need remains: advanced delivery systems capable of precisely targeting diverse tissues, particularly outside the liver. We also underscore the importance of rigorous target validation utilising sophisticated bioinformatics tools and in vitro/in vivo assays to minimise off-target effects and ensure robust therapeutic efficacy. This review proposes a novel framework for optimising RNA drug development, emphasising the crucial interplay between delivery strategies, target specificity, and understanding disease-specific target biology.

1 July 2018 in Journal of Clinical Virology
Verified
Journal Article
Closed access
TKTatiana Kuznetsova
Tatiana Kuznetsova
AIAnna Ivanova-Pozdejeva
Anna Ivanova-Pozdejeva
IRIrina Reshetnjak
Irina Reshetnjak
JGJulia Geller
Julia Geller
KVKairi Värv
Kairi Värv
IGIrina Golovljova
Irina Golovljova

Verified
Journal Article
Open access
PDF file
Natalia PozdniakovaNatalia Pozdniakova
Natalia Pozdniakova
OROxana Ryabaya
Oxana Ryabaya
ASAlevtina Semkina
Alevtina Semkina
VSVsevolod Andreevich Skribitsky
Vsevolod Andreevich Skribitsky
ASAlexei B. Shevelev
Alexei B. Shevelev
Three artificial proteins that bind the gadolinium ion (Gd3+) with tumour-specific ligands were de novo engineered and tested as candidate drugs for binary radiotherapy (BRT) and contrast agents for magnetic resonance imaging (MRI). Gd3+-binding modules were derived from calmodulin. They were joined with elastin-like polypeptide (ELP) repeats from human elastin to form the four-centre Gd3+-binding domain (4MBS-domain) that further was combined with F3 peptide (a ligand of nucleolin, a tumour marker) to form the F3-W4 block. The F3-W4 block was taken alone (E2-13W4 protein), as two repeats (E1-W8) and as three repeats (E1-W12). Each protein was supplemented with three copies of the RGD motif (a ligand of integrin αvβ3) and green fluorescent protein (GFP). In contrast to Magnevist (a Gd-containing contrast agent), the proteins exhibited three to four times higher accumulation in U87MG glioma and A375 melanoma cell lines than in normal fibroblasts. The proteins remained for >24 h in tumours induced by Ca755 adenocarcinoma in C57BL/6 mice. They exhibited stability towards blood proteases and only accumulated in the liver and kidney. The technological advantages of using the engineered proteins as a basis for developing efficient and non-toxic agents for early diagnosis of tumours by MRI as well as part of BRT were demonstrated.

1 August 2011 in Doklady Biochemistry and Biophysics
Verified
Journal Article
Closed access
PDF file
AGA. V. Godovannyi
A. V. Godovannyi
EVE. A. Vorontsov
E. A. Vorontsov
NGN. V. Gukasova
N. V. Gukasova
Natalia PozdniakovaNatalia Pozdniakova
Natalia Pozdniakova
EVE. A. Vasilenko
E. A. Vasilenko
NGN. V. Gnuchev
N. V. Gnuchev